NAUT - Nautilus Biotechnology Inc

NAUT - Nautilus Biotechnology Inc

https://www.nautilus.bio

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024

GlobeNewswire • 1 year, 2 months ago

SEATTLE, July 09, 2024 ( GLOBE NEWSWIRE ) -- Nautilus Biotechnology, Inc. ( NASDAQ: NAUT. or "Nautilus" ) , a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024.

Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Investing News Network • 1 year, 3 months ago • score: 0.14

Nautilus Biotechnology, Inc. ( NASDAQ: NAUT; or "Nautilus" ) , a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference.

Nautilus Biotechnology ( NAUT ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 1 year, 4 months ago • score: 0.37

Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

GlobeNewswire • 1 year, 5 months ago

SEATTLE, April 11, 2024 ( GLOBE NEWSWIRE ) -- Nautilus Biotechnology, Inc. ( NASDAQ: NAUT. or "Nautilus" ) , a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference

GlobeNewswire • 1 year, 6 months ago

SEATTLE, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- Nautilus Biotechnology, Inc. ( NASDAQ: NAUT. or "Nautilus" ) , a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is headquartered in Seattle, Washington.

52W High

$3.09

52W Low

$0.62

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.24

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.00

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.46

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

33.34%

Institutions (25–75% balanced)

46.34%

Shares Outstanding

126,305,000

Float

46,279,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.52

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.32%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0075

Previous

-0.0120

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025